Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Krystal Biotech (NASDAQ: KRYS) will report fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, before the U.S. market opens.
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) will report fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, before the U.S. market opens. Management will host a conference call and live webcast at 8:30 am ET that day to discuss results and provide a business update.
According to the company, the live webcast is available at the provided webcast link and a replay will be accessible for at least 30 days on the Investors section of the company website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – KRYS
On Feb 10, the day this news came out, KRYS closed 0.70% below the previous close.
Data tracked by StockTitan Argus for the Feb 10 session.
Key Figures
- Earnings release date
- February 17, 2026
- Scheduled fourth quarter and full year 2025 results
- Conference call time
- 8:30 am ET
- Earnings call and business update on February 17, 2026
- Webcast replay duration
- 30 days
- Replay available on company website
Historical Context
-
Positive interim KB407 Phase 1 CORAL-1 data in cystic fibrosis patients.
-
Announcement of investor call to share interim CORAL-1 KB407 clinical data.
-
Participation and presentation at the 44th Annual J.P. Morgan Healthcare Conference.
-
Presentation and investor meetings at the 8th Annual Evercore Healthcare Conference.
-
Third quarter 2025 financial and operating results including VYJUVEK revenue growth.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53598.
For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.